OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, …Read More